This inventor holds 1 USPTO granted patent and 4 published patent applications. Top assignee: Pure Tech Lyt 100, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Camilla S Graham: Innovator in Pulmonary Fibrosis Treatment
Introduction
Camilla S Graham is a notable inventor based in Framingham, MA (US). She has made significant contributions to the field of medicine, particularly in the treatment of idiopathic pulmonary fibrosis (IPF). Her innovative approach has the potential to improve the lives of many patients suffering from this challenging condition.
Latest Patents
Camilla holds a patent for "Methods of treating idiopathic pulmonary fibrosis with deupirfenidone." This patent discloses a method that includes administering deuterium-enriched pirfenidone, known as LYT-100, at a total daily dose ranging from about 1650 mg to about 2500 mg. This advancement represents a promising step forward in the management of IPF.
Career Highlights
Throughout her career, Camilla has demonstrated a commitment to advancing medical science. Her work at Pure Tech Lyt 100, Inc. has positioned her as a key player in the development of innovative treatments for pulmonary diseases. Her dedication to research and development has garnered attention in the medical community.
Collaborations
Camilla has collaborated with esteemed colleagues, including Michael C Chen and Simon John Hatch. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of her work in the field.
Conclusion
Camilla S Graham's contributions to the treatment of idiopathic pulmonary fibrosis exemplify the power of innovation in medicine. Her patent and ongoing research efforts highlight her role as a leading inventor in this vital area of healthcare.